ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
ANN ARBOR, Mich., April 11, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced that the company will deliver a podium presentation reviewing the results from a Phase 1 study to evaluate the safety of ONL1204 ophthalmic solution for the treatment of patients with macula-off rhegmatogenous retinal detachment (RRD) at the upcoming annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The ARVO Annual Meeting will take place April 23-27, 2023, at the Ernest N. Morial Convention Center in New Orleans, LA.